---
document_datetime: 2023-09-21 17:14:59
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/clopidogrel-1a-pharma-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: clopidogrel-1a-pharma-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.2700479
conversion_datetime: 2025-12-21 19:16:12.974028
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

## Clopidogrel 1A Pharma

Procedural steps taken and scientific information after the authorisation

<!-- image -->

| No      | Scope                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3 Summary longer   |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|-------------------------------------------------|
| IB/0005 | Amendments are introduced into the product information, in accordance with the respective amendments to the reference product, to include information on the clopidogrel metabolism pathway, the role of CYP2C19 genetic polymorphism on clopidogrel variability of response and the potential interaction between clopidogrel and CYP2C19 inhibitors including some proton pump inhibitors. Additionally, some minor amendments were made to up-date the product information with regard to QRD and to clear out the differences in wording in comparison to the reference product. | 06/08/2010 product                  | n/a no                                      | SPC, Labelling, PL                              |

1 Notifications are issued for type I variations (unless part of a group or a worksharing application). Opinions are issued for all other procedures.

2 No Commission Decision is issued for type IA and type IB variations or for type II variations and annual re-assessments that do not affect the annexes.

3 SPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

7 Westferry Circus

●

Canary Wharf

●

London E14 4HB

●

United Kingdom

Telephone +44 (0)20 7418 8400 Facsimile +44 (0) 20 7523 7455

E-mail info@ema.europa.eu

Website www.ema.europa.eu

Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

| No       | Scope                                                                                                                                                                                                                                                                                                                                 | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                            |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------|
| A20/0004 | Pursuant to Article 20 of Regulation (EC) No 726/2004 of 31 March 2004, the European Commission requested on 18 March 2010, the opinion of the CHMP on measures necessary to ensure the quality of the above mentioned medicinal product further to GMP deficiencies of the API manufacturing site Glochem Industries Ltd. (Unit II). | 18/03/2010                          | 16/09/2010                                  | longer                           | Please refer to the Assessment Report: Clopidogrel 1A Pharma-H-1054-A20-04-Assessment Report-Article 20 authorised |
| II/0003  | To register a revised version of the ASMF for clopidogrel besilate from the existing active substance manufacturer, introducing changes in the manufacturing process of the active substance. Quality changes                                                                                                                         | 21/01/2010                          | 04/02/2010 no                               |                                  |                                                                                                                    |
| IA/0001  | 07_a_Replacement/add. of manufacturing site: Secondary packaging site, 07_b_01_Replacement/add. of manufacturing site: Primary packaging site - Solid forms                                                                                                                                                                           | 25/08/2009 product                  | n/a                                         |                                  |                                                                                                                    |
| IA/0002  | 08_b_01_Change in BR/QC testing - repl./add. manuf. responsible for BR - not incl. BC/testing                                                                                                                                                                                                                                         | 24/08/2009                          | n/a                                         | SPC, Labelling, PL               |                                                                                                                    |